Comorbidity and survival in lung cancer patients

Km Islam, Xiaqing Jiang, Trisari Anggondowati, Ge Lin, Apar Kishor Ganti

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background: As the population of the United States ages, there will be increasing numbers of lung cancer patients with comorbidities at diagnosis. Comorbid conditions are important factors in both the choice of the lung cancer treatment and outcomes. However, the impact of individual comorbid conditions on patient survival remains unclear. Methods: A population-based cohort study of 5,683 first-time diagnosed lung cancer patients was captured using the Nebraska Cancer Registry (NCR) linked with the Nebraska Hospital Discharge Data (NHDD) between 2005 and 2009. A Cox proportional hazards model was used to analyze the effect of comorbidities on the overall survival of patients stratified by stage and adjusting for age, race, sex, and histologic type. Results: Of these patients, 36.8% of them survived their first year after lung cancer diagnosis, with a median survival of 9.3 months for all stages combined. In this cohort, 26.7% of the patients did not have any comorbidity at diagnosis. The most common comorbid conditions were chronic pulmonary disease (52.5%), diabetes (15.7%), and congestive heart failure (12.9%). The adjusted overall survival of lung cancer patients was negatively associated with the existence of different comorbid conditions such as congestive heart failure, diabetes with complications, moderate or severe liver disease, dementia, renal disease, and cerebrovascular disease, depending on the stage. Conclusions: The presence of comorbid conditions was associated with worse survival. Different comorbid conditions were associated with worse outcomes at different stages. Impact: Future models for predicting lung cancer survival should take individual comorbid conditions into consideration.

Original languageEnglish (US)
Pages (from-to)1079-1085
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume24
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Comorbidity
Lung Neoplasms
Survival
Heart Failure
Cerebrovascular Disorders
Diabetes Complications
Proportional Hazards Models
Population
Lung Diseases
Dementia
Registries
Liver Diseases
Chronic Disease
Cohort Studies
Kidney
Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Comorbidity and survival in lung cancer patients. / Islam, Km; Jiang, Xiaqing; Anggondowati, Trisari; Lin, Ge; Ganti, Apar Kishor.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 24, No. 7, 01.07.2015, p. 1079-1085.

Research output: Contribution to journalArticle

Islam, Km ; Jiang, Xiaqing ; Anggondowati, Trisari ; Lin, Ge ; Ganti, Apar Kishor. / Comorbidity and survival in lung cancer patients. In: Cancer Epidemiology Biomarkers and Prevention. 2015 ; Vol. 24, No. 7. pp. 1079-1085.
@article{afd110b07a6c45d295fb63e8f1e92efa,
title = "Comorbidity and survival in lung cancer patients",
abstract = "Background: As the population of the United States ages, there will be increasing numbers of lung cancer patients with comorbidities at diagnosis. Comorbid conditions are important factors in both the choice of the lung cancer treatment and outcomes. However, the impact of individual comorbid conditions on patient survival remains unclear. Methods: A population-based cohort study of 5,683 first-time diagnosed lung cancer patients was captured using the Nebraska Cancer Registry (NCR) linked with the Nebraska Hospital Discharge Data (NHDD) between 2005 and 2009. A Cox proportional hazards model was used to analyze the effect of comorbidities on the overall survival of patients stratified by stage and adjusting for age, race, sex, and histologic type. Results: Of these patients, 36.8{\%} of them survived their first year after lung cancer diagnosis, with a median survival of 9.3 months for all stages combined. In this cohort, 26.7{\%} of the patients did not have any comorbidity at diagnosis. The most common comorbid conditions were chronic pulmonary disease (52.5{\%}), diabetes (15.7{\%}), and congestive heart failure (12.9{\%}). The adjusted overall survival of lung cancer patients was negatively associated with the existence of different comorbid conditions such as congestive heart failure, diabetes with complications, moderate or severe liver disease, dementia, renal disease, and cerebrovascular disease, depending on the stage. Conclusions: The presence of comorbid conditions was associated with worse survival. Different comorbid conditions were associated with worse outcomes at different stages. Impact: Future models for predicting lung cancer survival should take individual comorbid conditions into consideration.",
author = "Km Islam and Xiaqing Jiang and Trisari Anggondowati and Ge Lin and Ganti, {Apar Kishor}",
year = "2015",
month = "7",
day = "1",
doi = "10.1158/1055-9965.EPI-15-0036",
language = "English (US)",
volume = "24",
pages = "1079--1085",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Comorbidity and survival in lung cancer patients

AU - Islam, Km

AU - Jiang, Xiaqing

AU - Anggondowati, Trisari

AU - Lin, Ge

AU - Ganti, Apar Kishor

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background: As the population of the United States ages, there will be increasing numbers of lung cancer patients with comorbidities at diagnosis. Comorbid conditions are important factors in both the choice of the lung cancer treatment and outcomes. However, the impact of individual comorbid conditions on patient survival remains unclear. Methods: A population-based cohort study of 5,683 first-time diagnosed lung cancer patients was captured using the Nebraska Cancer Registry (NCR) linked with the Nebraska Hospital Discharge Data (NHDD) between 2005 and 2009. A Cox proportional hazards model was used to analyze the effect of comorbidities on the overall survival of patients stratified by stage and adjusting for age, race, sex, and histologic type. Results: Of these patients, 36.8% of them survived their first year after lung cancer diagnosis, with a median survival of 9.3 months for all stages combined. In this cohort, 26.7% of the patients did not have any comorbidity at diagnosis. The most common comorbid conditions were chronic pulmonary disease (52.5%), diabetes (15.7%), and congestive heart failure (12.9%). The adjusted overall survival of lung cancer patients was negatively associated with the existence of different comorbid conditions such as congestive heart failure, diabetes with complications, moderate or severe liver disease, dementia, renal disease, and cerebrovascular disease, depending on the stage. Conclusions: The presence of comorbid conditions was associated with worse survival. Different comorbid conditions were associated with worse outcomes at different stages. Impact: Future models for predicting lung cancer survival should take individual comorbid conditions into consideration.

AB - Background: As the population of the United States ages, there will be increasing numbers of lung cancer patients with comorbidities at diagnosis. Comorbid conditions are important factors in both the choice of the lung cancer treatment and outcomes. However, the impact of individual comorbid conditions on patient survival remains unclear. Methods: A population-based cohort study of 5,683 first-time diagnosed lung cancer patients was captured using the Nebraska Cancer Registry (NCR) linked with the Nebraska Hospital Discharge Data (NHDD) between 2005 and 2009. A Cox proportional hazards model was used to analyze the effect of comorbidities on the overall survival of patients stratified by stage and adjusting for age, race, sex, and histologic type. Results: Of these patients, 36.8% of them survived their first year after lung cancer diagnosis, with a median survival of 9.3 months for all stages combined. In this cohort, 26.7% of the patients did not have any comorbidity at diagnosis. The most common comorbid conditions were chronic pulmonary disease (52.5%), diabetes (15.7%), and congestive heart failure (12.9%). The adjusted overall survival of lung cancer patients was negatively associated with the existence of different comorbid conditions such as congestive heart failure, diabetes with complications, moderate or severe liver disease, dementia, renal disease, and cerebrovascular disease, depending on the stage. Conclusions: The presence of comorbid conditions was associated with worse survival. Different comorbid conditions were associated with worse outcomes at different stages. Impact: Future models for predicting lung cancer survival should take individual comorbid conditions into consideration.

UR - http://www.scopus.com/inward/record.url?scp=84941774745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941774745&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-15-0036

DO - 10.1158/1055-9965.EPI-15-0036

M3 - Article

VL - 24

SP - 1079

EP - 1085

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -